1973 Budapest, Hungary - start of the establishment of the Cyclolab profile, which initiates comprehensive research and development in the field of cyclodextrins (CD).

1975-1985 The CD concept takes the form of project proposals with technological documentation (product development, CD production processes).

1982 First safety/toxicological studies on a-, b- and yCD are carried out.

1985 The laboratory specialists complete the synthesis of HPBCD (2-hydroxypropyl-betadex) and DIMEB (heptakis - 2,6- di-O-methyl-betacyclodextrin) and the creation of DMF for HPBCD.

2006 The integration of Cyclolab into the Swiss QD group is finalised, thus combining potentials.

1992-2005 - QD technology is founded, where bioparticle structures of a special class of Quantum Dots (QD), i.e. APIs for regulated synthesis of reactive oxygen species (ROS) in vertebrates, pioneered the creation of a new generation of formulation series.

2005-2007 - GMP validation and scale-up of substance and drug series release, regulatory approval of clinical trials. Wide range of formulations with Dexolve, DIMEB, HPBCD, HPGCD products as part of the compositions - demonstrating the potential of API properties.

1993-2024 - Performed CTAs to initiate a series of clinical trials for 15 groups of nosologies including a variety of formulation variations.